A trial fibrillation (AF) is a common arrhythmia associated with a broad spectrum of underlying diseases that include systemic hypertension, rheumatic heart disease and coronary artery disease.' Several studies have documented the strong relation between chronic AF and emboli.2J In addition, an increased risk of embolism exists in the setting of cardioversion of AF to sinus rhythm.4T5 In the best study to date, Bjerkelund and Orning6 reported on 572 attempted cardioversions in 437 patients and observed a 0.8% incidence of embolization in long-term anticoagulated patients compared with 5.3% in a nonanticoagulated group. Shortcomings of this study included lack of randomization, no evaluation of shortterm therapy and inclusion of arrhythmias such as atria1 flutter and atria1 tachycardia. Based on such work, current recommendations include anticoagulation for 2 to 4 weeks before cardioversion to allow adherence and endothelialization of existing thrombus and 1 to 4 weeks after cardioversion to provide coverage for late resumption of atria1 activity.7s8 The present report evaluates these recommendations in light of our experience over the past 10 years.
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The University of Michigan Hospital's Medical Information Department identified 150 patients with AF who underwent cardioversion over the study decade. After 105 patient charts were located from that total, 79 patients were deemed appropriate for study and 26 were excluded. Exclusion criteria included rhythm disturbances other than AF and transient episodes of AF during cardiopulmonary arrest or after cardiac surgery (<24 hours). A cerebral embolism was considered present and related to the cardioversion if a circumscribed focal deficit developed within 2 weeks of cardioversion.9 All events occurred, however, within 72 hours.
Most patients were men (57%) and a significant percentage had underlying organic disease (see later), Age ranged from I6 to 84 years. Approximately 14% (11 patients) had a history of prior stroke or transient ischemic attack. Of those, a third (4 of 11) experienced an embolic event at the time of presentation with new onset ofAF. Approximately 10% ofpatients had either clinical (elevated jugular venous pressure, S3, rales) or radiologic evidence of congestive heart failure. One half of the study population received digoxin before cardioversion. Bundle branch block was found in 10 (13%) patients.
Duration of AF ranged from <48 hours to >12 months. It lasted <48 hours in 19 (24%) patients, 48 hours to 2 weeks in 16 (20%), from 2 weeks to 6 months in 24 (30%) and >6 months in 18 (23%). Echocardiograms were performed in 52 of the 79 patients. Approximately 62% (32 of 52) were found to have left atria1 enlargement (>#0 mm). Almost a third had mitral (10 of 52) or aortic (6 of 52) valvular abnormalities. Left ventricular dysfunction was found in 31% (16 of 52) of these patients. Radionuclide angiograms were available in 38% of the study population and ejection fractions <45% were documented in 18 patients. The majority (93%) was electrically cardioverted (7% pharmacologically).
Successful conversion to normal sinus rhythm was accomplished in 84% of the patients. The duration of sinus rhythm ranged from 12 hours to >5 years.
Sixty-two percent of patients who did not experience cardioversion-related emboli were anticoagulated before cardioversion, most for <I month. A relatively small number (8 of 48) of those who did not experience an embolic event received long-term anticoagulation (>I year). Criteria for therapeutic anticoagulation included a prothrombin time 1.5 to 2.0 times the control values. Prothrombin times (by rabbit brain thromboplastin) were obtained within 72 hours of cardioversion in all patients receiving anticoagulation therapy. Prothrombin times were obtained randomly in the 28patients who did not receive anticoagulation.
None of the anticoagulatedpatients had a cardioversion-related stroke. In contrast, 7% (2 of 28) who were not anticoagulated or who received <2 days of heparin therapy ("nonanticoagulated group") had an embolic complication. By studying the patients who experienced a stroke, a "high-risk" subgroup emerged, comprised of patients >55 years who had coronary heart disease, cardiomyopathy or hypertension or both, and duration of AF >I year. Fifty percent of the nonanticoagulated patients in this subgroup had an embolic complication. Five others fitting this subgroup definition who received short-term anticoagulation had no complications.
Hemorrhagic complications were seen in 8 patients (10%). One patient had only minimal bruising. Seven other bleeding events were noted per 16,440 anticoagulated patient days (0.16 events/patient-year). Specific complications included hematuria (2patients), epistaxis (2), guaiacpositive stool (I), menorrhagia (1) and divertitular gastrointestinal bleeding (1) . Among the 51 patients who were anticoagulated, 14% experienced a bleeding complication. No hemorrhagic events occurred in the 28 patients not anticoagulated. Of note, no bleeding events were seen among those patients who received short-term (<I month) anticoagulation therapy. Hemorrhagic complications occurred almost exclusively in the subset of patients receiving long-term anticoagula- Of the study population overall, 2 patients had pericardioversion-related embolus (equal to 7% of the nonanticoagulated cohort). Both had cardiomegaly, longduration AF (> 1 year) and were either receiving no anticoagulants or had <2 days of heparin therapy. In contrast, no embolic events were observed in the group of patients therapeutically anticoagulated. Patients with underlying organic heart disease and long-standing AF are least likely to be successfully cardioverted and maintained in sinus rhythm,lO although in this instance both patients were successfully cardioverted.
The risks of anticoagulation provide strong motivation to forego this prophylactic therapy in many patients requiring cardioversion. Whereas 14% of anticoagulated patients in this study experienced a bleeding episode, only 2% were life-threatening. Of importance is the fact that no bleeding complications occurred among patients receiving short-term (<l month) anticoagulation in this study. Well-managed, short-term anticoagulation of selected patients appears to be a beneficial prophylactic maneuver, with little risk of significant hemorrhagic sequelae. Given the small sample size, this conclusion is still presumptive. A large, controlled study would be desirable to more definitively assess the utility of anticoagulation in this common clinical situation. In the interim, our experience supports consideration of short-term anticoagulation when cardioversion of AF is indicated. Eighteen consecutive patients including 14 men and 4 women, aged 41 f 18 years (range 20 to 72), with symptomatic preexcitation syndrome were studied before and after oral flecainide or encainide. In 1 patient a concealed bypass tract was present, while in the remaining 17 preexcitation was manifest. Presenting symptoms included palpitations in 3 patients, presyncope in 9 patients and syncope in 6 patients. The presenting clinical arrhythmia was reciprocating tachycardia in 10 patients From the Cardiac Arrhythmia Service, Division of Cardiology, Department of Medicine, Tufts University School of Medicine, 750 Washington Street, Boston, Massachusetts 02111. Manuscript received October 3 1,1988 ; revised manuscript received and accepted December 12,1988. and atria1 fibrillation in 8 patients. In 2 patients atria1 fibrillation degenerated into ventricular fibrillation. The average number of previous unsuccessful drug trials bey;fz;lr electrophysiologic study was 1.9 f 1 .O ran e All patients underwent baseline electrophysiologic study in the drug-free state. The programmed electrical stimulation was performed using standard techniques.4-6 Atrialfibrillation was initiated in all patients by rapid burst atrialpacing. After the baseline study, 12 patients received oralflecainide in dosages of 100 to 200 mg twice daily for 4 days (mean daily dose 250 f 76 mg) and Spatients received oral encainide in doses of 2.5 to 50 mg thrice daily for 3 days (mean daily dose 108 f 24 mg) before follow-up evaluation. One patient initially placed on encainide had an increase in the frequency of reciprocating tachycardia occurrences without prolongation of the retrograde refractory period of the bypass tract. This patient wasswitchedfrom encainide toflecainide with improved clinical and electrophysiologic results. Serum levels of encainide and its metabolites were not obtained at follow-up studies. Flecainide serum levels averaged 0.6 f 0.2 mgjliter (range 0.4 to 0.9).
All patients were followed clinically at the Cardiac Arrhythmia Clinic at 3-month intervals as well as by
